<DOC>
	<DOCNO>NCT01016483</DOCNO>
	<brief_summary>The research trial test experimental treatment MSC1936369B combination Gemcitabine , subject metastatic pancreatic adenocarcinoma . The study run two part : Safety Run-In : Will determine Maximum Tolerated Dose ( MTD ) recommend Phase II dose MSC1936369B , combine gemcitabine , subject metastatic pancreatic adenocarcinoma . Phase II : Will assess anti-tumor activity MSC1936369B combine gemcitabine compare gemcitabine alone first line treatment subject metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Trial Gemcitabine With Without MSC1936369B Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Subject provide sign informed consent . Fully understand requirement trial willing comply trial visit assessment . 2 . Histologically cytologically confirm metastatic adenocarcinoma pancreas availability tumor sample . 3 . Evidence disease ( necessarily measurable disease ) . Complete tumor assessment include chest X ray , CT scan abdomen scan necessary document site disease perform within 28 day prior trial entry/randomization . 4 . Age â‰¥ 18 year . 5 . Women childbearing potential must negative blood pregnancy test screen visit . For purpose trial , woman childbearing potential define : `` All female subject puberty unless postmenopausal least two year , surgically sterile sexually inactive . '' 6 . Female subject childbearing potential male subject female partner childbearing potential must willing avoid pregnancy use adequate method contraception 2 week prior screen , four week last dose trial medication . Adequate contraception define two barrier method , one barrier method spermicide , intrauterine device . The use hormonal contraceptive avoid female subject childbearing potential due possible drugdrug interaction . 1 . Bone marrow impairment evidence hemoglobin &lt; 9.0 g/dL , neutrophil count &lt; 1.5 x 10^9/L , platelet &lt; 100 x 10^9/L . 2 . Renal impairment evidence serum creatinine &gt; 1.5 x upper limit normal ( ULN ) , and/or calculate creatinine clearance &lt; 60 mL/min . 3 . Liver function abnormality define total bilirubin &gt; 1.5 x ULN , AST/ALT &gt; 2.5 x ULN , subject liver involvement AST/ALT &gt; 5 x ULN . 4 . Serum calcium &gt; 1 x ULN . 5 . History central nervous system ( CNS ) metastases , unless subject previously treat CNS metastasis , stable CT scan without evidence cerebral edema , requirement corticosteroids anticonvulsant . 6 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) great 1 . 7 . Significant cardiac conduction abnormality , include QTc prolongation &gt; 480 m and/or pacemaker . 8 . Retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , history uveitis history retinal vein occlusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>cancer</keyword>
	<keyword>pancreatic Adenocarcinoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>chemo-naive</keyword>
	<keyword>phase II</keyword>
</DOC>